The characterization and molecular structure of hepatoproliferin: a liver regeneration factor from rat hepatocytes.

Hepatoproliferin (HPF) was purified from regenerating rat livers as an oligomeric entity (big-HPF) from which the monomeric form (small-HPF) could be obtained using disaggregating conditions. By using a solid-phase ion-exchange method, small-HPF was forced to dissociate into two charged ionic species, namely norepinephrine (NE) and a sulfonated disaccharide with a molecular structure consisting of D-glucuronic acid bound to glucosamine 2,6-disulfate by a beta-glycosidic linkage having a beta, 1 --> 4 configuration. Monomeric HPF stemmed from the formation of three electrostatic bonds between the protonated amine groups of three norepinephrines, of which two bind to the deprotonated sulfonic groups of glucosamine 2,6-disulfate and one to the deprotonated carboxylic group of glucuronic acid, to constitute a tightly associated complex with a molecular mass of 1046 Da. This represents one of the two purified isoforms of small-HPF. The other isoform, which has a lower molecular mass of 877 Da, lack one NE, leaving the weaker carboxylic group of glucuronic acid unoccupied, to constitute a more acidic form of HPF.

Oligomeric hepatoproliferin disaggregates into an active monomer that was purified and forcefully dissociated into two different ionic species.

Hepatoproliferin (HPF), a liver regeneration factor, was isolated initially as an aggregated molecule (big-HPF) and was purified into two homogeneous, bioactive species of 14 kDa and 18.5 kDa. These two big-HPFs were disaggregated to completion into two monomeric forms (small-HPFs) when incubated for 10 days in 0.15 M ammonium bicarbonate at 25 degrees C. Both monomeric forms were purified to homogeneity as active entities, one with a molecular mass of 944 Da and one with a molecular mass of 1066 Da. Each of the two (35)S-labelled small-HPFs was found, by enzymic analysis, to contain a charged sulfonated saccharide, which was neutralized by a specific amine. Monomeric HPF is therefore a stable ionic complex formed between these two ionic species. So strong was the electrostatic association that small-HPF remained intact in solution and no amine was displaced by the ammonium ions of the buffer. Small-HPF remained unimpaired during purification, since all activity was retained despite alternating acidic and basic conditions. However, when small-HPF was brought into contact with either a cationic or an anionic resin, it was dissociated to completion when mixed continuously with the resin for 4 days. The ionic entity that was released had no bio-activity and was either a pure radioactively labeled saccharide or a non-labeled amine, depending on the kind of resin used. When incubated together, the separated counterions combine to regain full activity after 2 days of reassociation. However, with incubation for longer, this reassociated small-HPF formed different oligomeric HPFs by aggregation. Small-HPF is therefore a new kind of growth enhancer, consisting of an acidic sulfonated saccharide and a basic amine assembled into a stable active ionic complex that has a tendency to aggregate.

The prevalence and purification of hepatoproliferin: a liver regeneration factor from rat hepatocytes.

Hepatoproliferin (HPF), a liver regeneration factor that was able to augment the growth of hepatocytes in the presence of EGF, was produced by young rat livers and hepatectomized adult livers (70%), but not by adult intact livers. Therefore only growing and regenerating livers produce HPF. This growth factor was purified into two homogeneous bioactive species having different single SDS-PAGE bands at 18.5 and 14 kDa, and different single pI-bands at pH 4.3 and 8.7, respectively. HPF was synthesized de novo by hepatocytes in the liver as shown by the in vivo incorporation of radiolabeled 35S-sulfate and 14C/3H-glucosamine. This radioactive HPF was secreted ex vivo by hepatocytes, probably to act as an autocrinal hepatomitogen since 90% was found in the growth medium. HPF was neither a classical peptido-mitogen nor a heparin binding growth factor, but a liver-originated non-proteinaceous factor, which probably contains sulfonated saccharides such as glucosamine sulfate. HPF was neither a polyglycan nor a glycopeptide nor a peptidoglycan.

Pharmacologic options for the treatment of obesity.

Past and current drug therapies for weight loss are discussed. More than 50% of Americans can be categorized as overweight or obese. Obesity is associated with increased mortality and with comorbidities such as hypertension, hyperglycemia, dyslipidemia, coronary artery disease, and certain cancers. According to guidelines for identification, evaluation, and treatment of obesity, patients with a body mass index (BMI) of > or = 30 kg/m2 should attempt to lose weight. Patients with a BMI of > or = 25 kg/m2 plus two or more risk factors or patients with an excessive waist circumference plus two or more risk factors should also attempt to lose weight. The initial goal is a 10% weight reduction in six months achieved through lifestyle changes. If lifestyle changes alone are not effective, then drug therapy may be indicated. Pharmacotherapeutic options for obesity have decreased over the past few years. Fenfluramine, dexfenfluramine, and phenylpropanolamine have been withdrawn because of severe adverse effects, leaving only sympathomimetics, sibutramine, and orlistat as anorectics with FDA-approved labeling. Phentermine has been shown to cause a 5-15% weight loss if given daily or intermittently. Compared with sibutramine and orlistat, phentermine is cheaper, and specific formulations allow once-daily administration. However, phentermine is indicated only for short-term treatment, and tolerance often develops. Common adverse effects associated with phentermine are dry mouth, insomnia, increased blood pressure, and constipation. Sibutramine increases norepinephrine and serotonin levels in the CNS and should not be taken with many antidepressants because of the risk of increased norepinephrine and serotonin levels. Its use is also contraindicated in patients with cardiovascular disease. Orlistat is not systemically absorbed; therefore, it does not cause the systemic adverse effects or drug interactions of phentermine and sibutramine. Orlistat has a cholesterol-lowering effect not seen with other diet medications. However, the three-times-daily administration and frequent gastrointestinal effects limit its use. Sibutramine, phentermine, and orlistat have both positive and negative properties. Choosing among the medications will depend on concurrent disease states and medications, ease of administration, and cost.

Structural features that modulate the transmembrane migration of a hydrophobic peptide in lipid vesicles.

Two approaches employing nuclear magnetic resonance (NMR) were used to investigate the transmembrane migration rate of the C-terminal end of native alamethicin and a more hydrophobic analog called L1. Native alamethicin exhibits a very slow transmembrane migration rate when bound to phosphatidylcholine vesicles, which is no greater than 1 x 10(-4) min(-1). This rate is much slower than expected, based on the hydrophobic partition energies of the amino acid side chains and the backbone of the exposed C-terminal end of alamethicin. The alamethicin analog L1 exhibits crossing rates that are at least 1000 times faster than that of native alamethicin. A comparison of the equilibrium positions of these two peptides shows that L1 sits approximately 3-4 A deeper in the membrane than does native alamethicin (Barranger-Mathys and Cafiso. 1996. Biochemistry. 35:489). The slow rate of alamethicin crossing can be explained if the peptide helix is irregular at its C-terminus and hydrogen bonded to solvent or lipid. We postulate that L1 does not experience as large a barrier to transport because its C-terminus is already buried within the membrane interface. This difference is most easily explained by conformational differences between L1 and alamethicin rather than differences in hydrophobicity. The results obtained here demonstrate that side-chain hydrophobicity alone cannot account for the energy barriers to peptide and protein transport across membranes.

Membrane structure of voltage-gated channel forming peptides by site-directed spin-labeling.

Three spin-labeled derivatives of the voltage-gated peptide alamethicin were prepared with nitroxides at the C-terminal phenyalaninol, and at positions 9 and 15 in the amino acid sequence. In addition, three spin-labeled derivatives of an analog of alamethicin where alpha-methylalanine residues are replaced by leucine were prepared with nitroxide labels at the same positions. Continuous wave power saturation EPR spectroscopy was used to examine the effect of molecular oxygen and water soluble paramagnetic reagents on the saturation behavior of the labeled peptides. Using the gradients of these species which exist through the membrane-solution interface, distances for these nitroxide derivatives from the membrane-solution interface were estimated. The distances show that alamethicin is inserted along the bilayer normal with the C-terminus of the peptide lying in the aqueous solution 3 or 4 A from the membrane interface. In this configuration alamethicin does not completely cross the bilayer, and the N-terminus of alamethicin is within the membrane hydrocarbon approximately 16 A from the phosphate groups on the opposing interface. The analog where leucines replace alpha-methylalanines shows a similar conformation, except that the entire peptide is translated 3-4 A deeper into the membrane than is native alamethicin. The distances that are measured for alamethicin using EPR are consistent with a linear high resolution NMR structure determined in SDS and the X-ray crystal structure. The membrane position and structure of alamethicin found here limit the likely models for voltage-gating of this peptide.

Membrane orientation of the N-terminal segment of alamethicin determined by solid-state 15N NMR.

Alamethicin was synthesized with 15N incorporated into alanine at position 6 in the peptide sequence. In dispersions of hydrated dimyristoylphosphatidylcholine, solid-state 15N NMR yields an axially symmetric powder pattern indicating that the peptide is reorienting with a single axis of symmetry when associated with lamellar lipids. When incorporated into bilayers that are uniformly oriented with the bilayer normal parallel to the B(o) field, the position of the observed 15N chemical shift is 171 ppm. This is coincident with the sigma parallel to edge of the axially symmetric powder pattern for non-oriented hydrated samples. Thus the axis of motional averaging lies along the bilayer normal. Two-dimensional separated local field spectra were obtained that provide a measure of the N-H dipolar coupling in one dimension and the 15N chemical shift in the other. These data yield a dipolar coupling of 17 kHz corresponding to an average angle of 24 degrees for the N-H bond with respect to the B(o) field axis. An analysis of the possible structures and orientations that could produce the observed spectral parameters show that these values are consistent with an alpha-helical conformation inserted along the bilayer normal.

Collisions between helical peptides in membranes monitored using electron paramagnetic resonance: evidence that alamethicin is monomeric in the absence of a membrane potential.

Alamethicin is a 20-amino-acid peptide that produces a voltage-dependent conductance in membranes. We investigated the state of aggregation of alamethicin in egg phosphatidylcholine and dioleoylphosphatidylcholine membranes by examining the EPR spectra obtained from an active analog of this peptide that is spin-labeled at its C-terminus. The dependence of both the linewidth and signal intensity as a function of peptide concentration exhibit exchange broadening as the peptide concentration is increased; however, the exchange rates are linear with peptide concentration as is expected for the simple diffusion of monomers. In addition, the spin-exchange rates obtained from the linebroadening are consistent with collisional rates that are predicted from free Brownian diffusion. The results provide strong evidence that in the absence of a membrane potential, alamethicin is largely monomeric in these membranes.